American Medical Systems® (AMS) (Nasdaq: AMMD), a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the launch and immediate availability of its new GreenLight XPS (Xcelerated Performance System) for laser treatment of benign prostatic hyperplasia (BPH) or enlarged prostate.
Built upon the technology and performance of AMS' GreenLight PV® and HPS laser systems, the new GreenLight XPS offers enhanced treatment efficiency with extended fiber longevity and improved coagulation capabilities over other laser therapy treatment systems. GreenLight™ has proven to deliver results equivalent to TURP, with lower morbidity, fewer complications, shorter hospital stays and lower overall cost.
"GreenLight XPS provides the most compelling alternative to TURP therapies and furthers our commitment to fostering a new standard of care for treating enlarged prostate," said Joe Martin, Senior Vice President and General Manager of BPH Therapies at AMS. "With these advances in our GreenLight system, we're one step closer to realizing our vision of a world without TURP and its bothersome side effects."
Faster, More Efficient Treatment with Greater Fiber Longevity
GreenLight XPS significantly improves vaporization efficiency leading to a reduction in treatment time without impacting the depth of tissue removal or coagulation.
The XPS system features FiberLife™, an automatic safety feature that decreases fiber-related failures by up to 90 percent resulting in increased longevity, enabling the treatment of glands larger than 100g with a single fiber.
"I am very pleased with the performance of the new GreenLight laser," said Ricardo Gonzalez, M.D., Houston Metro Urology/Baylor College of Medicine, who participated in the clinical evaluation of the GreenLight XPS Laser System. "The new FiberLife feature improves procedural efficiency and fiber reliability allowing treatment of larger glands with one fiber."
Squid-inspired technology could replace needles for medications and vaccines